Renal dysfunction in acute heart failure: Epidemiology, mechanisms and assessment

Heart Failure Reviews

Volumn 17, Issue 2, 2012, Pages 271-282

  Carubelli, Valentina ^a   Metra, Marco ^a   Lombardi, Carlo ^a   Bettari, Luca ^a   Bugatti, Silvia ^a   Lazzarini, Valentina ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute heart failure; Cardiorenal syndrome; Renal dysfunction

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR ALPHA; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FUROSEMIDE; KIDNEY INJURY MOLECULE 1; LEVOSIMENDAN; LOOP DIURETIC AGENT; N ACETYL BETA GLUCOSAMINIDASE; NAXIFYLLINE; NESIRITIDE; NEUROHORMONE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RENIN INHIBITOR; ROLOFYLLINE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; URODILATIN; VASOPRESSIN ANTAGONIST;

ACUTE HEART FAILURE; ADD ON THERAPY; ARTICLE; CARDIORENAL SYNDROME; CLINICAL ASSESSMENT; COMPLICATION; CREATININE BLOOD LEVEL; DETERIORATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEART FAILURE; HEART OUTPUT; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY VEIN; LOW DRUG DOSE; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; UREA NITROGEN BLOOD LEVEL; VENOUS CONGESTION; VENOUS PRESSURE;

BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; CREATININE; HEART FAILURE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; PROGNOSIS; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84862575515     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9265-z     Document Type: Article

References (117)

1. Thom T, Haase N, Rosamond W, et al (2006) Heart Disease and stroke Statistics-2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2006;113: e696]. Circulation 113: e85-e151
2. Haldeman GA, Croft JB, Giles WH, Rashidee A (1999) Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 137: 352-360
3. Cleland JG, Swedberg K, Follath F et al (2003) The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24: 442-463
4. Gheorghiade M, Zannad F, Sopko G, et al, for the International Working Group on Acute Heart Failure Syndromes (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112: 3958-3968
5. Gheorghiade M, Gattis WA, O'Connor CM, et al, for the Acute and Chronic Therapeutic Impact of a Vasopression Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291: 1963-1971
6. Adams KF Jr, Fonarow GC, Emerman CL, et al, for the ADHERE Scientific Advisory Committee and Investigators (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149: 209-216
7. Hillege HL, Girbes AR, de Kam PJ et al (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210
8. Dries DL, Exner DV, Domanski MJ et al (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681-689
9. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY (1998) Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992-999
10. Nohria A, Hasselblad V, Stebbins A et al (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51: 1268-1274
11. Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR et al (2007) Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 99: 393-398
12. Hillege HL, Nitsch D (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113: 671-678
13. Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 6(364): 11-21
14. Butler J, Chirovsky D, Phatak H et al (2010) Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail 3: 726-745
15. Smith GL, Lichtman JH, Bracken MB et al (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47: 1987-1996
16. Gottlieb SS, Abraham W, Butler J et al (2002) The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8: 136-141
17. Forman DE, Butler J, Wang Y et al (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43: 61-67
18. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL (2007) Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13: 599-608
19. Griendling KK, Minieri CA, Ollerensaw JD, Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148
20. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171
21. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK (2003) Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63: 179-185
22. Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP (2010) The role of nervous activity in renal injury and end-stage renal disease. Hypertens Res 33(6): 521-528
23. Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275-1281
24. McClellen W, Aronoff SL, Bolton WK et al (2004) The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20: 1501-1510
25. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, She L, Sun JL, Yancy CW, Fonarow GC, for the OPTIMIZE-HF Investigators and Coordinators (2008) Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 101: 223-230
26. George J, Patal S, Wexler D et al (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165: 1304-1309
27. Calvillo L, Latini R, Kajstura J et al (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802-4806
28. Vesey DA, Cheung C, Pat B et al (2004) Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19: 348-355
29. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9(9): 872-878
30. McCullough PA, Ahmad A (2001) Cardiorenal syndromes. World J Cardiol 26;3(1): 1-9
31. Mullens W, Abrahams Z, Francis GS et al (2009) Importance of venous congestion for worsening renal function in advanced decompensated heart failure. J Am Coll Cardiol 53: 589-596
32. Damman K, van Deursen VM, Navis G et al (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53: 582-588
33. Mullens W, Abrahams Z, Skouri HN et al (2008) Elevated intraabdominal pressure in acute decompensated heart failure. J Am Coll Cardiol 51: 300-306
34. Damman K, Voors AA, Hillege HL et al (2010) Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 12: 974-982
35. Uthoff H, Breidthardt T, Klima T et al (2011) Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail 13(4): 432-439
36. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M (1997) Plasma adenosine levels increase in patients with chronic heart failure. Circulation 95: 1363-1365
37. Metra M, Brutsaert D, Dei Cas L, Gheorghiade M (2011) Chapter 49 acute heart failure: epidemiology, classification, and pathophysiology. The ESC textbook of acute and intensive cardiac care 1(1): med-9780199584314-chapter- med-978019958 4314-chapter
38. Metra M, O'Connor CM, Davison BA, et al (2011) Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J, 8 Mar 2011 [Epub ahead of print]
39. Knight EL, Glynn RJ, McIntyre KM et al (1999) Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 138: 849-855
40. Metra M, Nodari S, Parrinello G et al (2008) Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 10: 188-195
41. De Silva R, Nikitin NP, Witte KKA et al (2006) Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 27: 569-581
42. Mielniczuk LM, Tsang SW, Desai AS et al (2008) The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 14: 388-393
43. Felker GM, O'Connor CM, Braunwald E; Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2: 56-62
44. Metra M, Bugatti S, Bettari L, et al (2011) Can we improve the treatment of congestion in heart failure? Expert Opin Pharmacother, 23 Feb 2011 [Epub ahead of print]
45. Jentzer JC, DeWald TA, Hernandez AF (2010) Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56: 1527-1534
46. Hasselblad V, Gattis Stough W, Shah MR et al (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9: 1064-1069
47. Felker et al (2011) Determining optimal dose and duration of diuretic treatment in people with acute heart failure (DOSEAHF). N Engl J Med (in press)
48. Maskin CS, Ocken S, Chadwick B, LeJemtel TH (1985) Comparative systemic and renal effects of dopamine and angiotensin- converting enzyme inhibition with enalaprilat in patients with heart failure. Circulation 72: 846-852
49. Elkayam U, Ng TM, Hatamizadeh P et al (2008) Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 117: 200-205
50. Friedrich JO, Adhikari N, Herridge MS, Beyene J (2005) Metaanalysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142: 510-524
51. Kellum JA, Decker J (2001) Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 29: 1526-1531
52. Giamouzis G, Butler J, Starling RC et al (2010) Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 16: 922-930
53. Leier CV, Heban PT, Huss P et al (1978) Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 58: 466-475
54. Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M (2009) Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev 14: 309-319
55. Publication Committee for the VMAC Investigators (Vasodilatation in the Management oacknerf Acute CHF) (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287: 1531-1540
56. O'Connor CM, Hernandez AF, Starling RC et al (2009) Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 157: 271-277
57. Hunt SA, Abraham WT, Chin MH et al (2009) Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 119: e391-e479
58. Lindenfeld J, Albert NM, Boehmer JP et al (2010) Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16: 475-539
59. Voors AA, van Veldhuisen DJ (2010) Cardiorenal effects of recombinant human natriuretic peptides. J Am Coll Cardiol 55: 1852-1853
60. Wang DJ, Dowling TC, Meadows D et al (2004) Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110: 1620-1625
61. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293: 1900-1905
62. Hernandez AF, O'Connor CM, Starling RC et al (2011) Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). New Engl J Med (in press)
63. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K (2005) Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 69(3): 283-290
64. Ren Y, Garvin JL, Carretero OA (2001) Efferent arteriole tubuloglomerular feedback in the renal nephron. Kidney Int 59: 222-229
65. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC; CKI-201 and CKI-202 Investigators (2007) The effects of KW- 3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50: 1551-1560
66. Cotter G, Dittrich HC, Weatherley BD et al (2008) The PROTECT pilot study: a randomized, placebo-controlled, dosefinding study of the adenosine A1 receptorantagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 14: 631-640
67. Metra M, O'Connor CM, Davison BA, et al (2011) Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J, ehr042 first published online 8 Mar 2011. doi: 10.1093/eurheartj/ehr042
68. Massie BM, O'Connor CM, Metra M et al (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363: 1419-1428
69. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F (2010) Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 28: 436-440
70. Herget-Rosenthal S, Marggraf G, Hüsing J et al (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int 66: 1115-1122
71. Haase-Fielitz A, Bellomo R, Devarajan P et al (2009) Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery-a prospective cohort study. Crit Care Med 37: 553-560
72. Waikar SS, Bonventre JV (2008) Biomarkers for the diagnosis of acute kidney injury. Nephron Clin Pract 109(4): c192-c197
73. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354: 2473-2483
74. Kunzendorf U, Haase M, Rölver L, Haase-Fielitz A (2010) Novel aspects of pharmacological therapies for acute renal failure. Drugs 70: 1099-1114
75. Waikar SS, Bonventre JV (2009) Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 20: 672-679
76. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122: 265-272
77. Costanzo MR, Guglin ME, Saltzberg MT et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49: 675-683
78. Filippatos G, Rossi J, Lloyd-Jones DM et al (2007) Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 13: 360-364
79. Cauthen CA, Lipinski MJ, Abbate A et al (2008) Relation of blood urea nitrogen to longterm mortality in patients with heart failure. Am J Cardiol 101: 1643-1647
80. Aronson D, Mittleman MA, Burger AJ (2004) Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116: 466-473
81. Klein L, Massie BM, Leimberger JD et al (2008) Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 1: 25-33
82. Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1: 2-5
83. Grubb A (1992) Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38: S20-S27
84. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb A et al (1995) Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47: 312-318
85. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson Ehle P, Lindstrom V et al (1994) Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40: 1921-1926
86. Grubb A, Simonsen O, Sturfelt G et al (1985) Serum concentration of cystatin C, factor D and 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 218: 499-503
87. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H (2000) Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 54: 203-209
88. Meir P, Froidevaux C, Dayer E, Blanc E (2001) Cystatin C concentration and glomerular filtration rate. Lancet 357: 634-635
89. Herget-Rosenthal S, Trabold S, Pietruck F, Heemann U, Philipp T, Kribben A (2000) Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 20: 97-102
90. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO et al (1994) Serum cystatin C: a replacement for creatinine as a biochemical marker for GFR. Kidney Int 46: S20-S21
91. Lassus JP, Nieminen MS, Peuhkurinen K et al (2010) Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 31: 2791-2798
92. Kai M, Schmidt-Ott KM, Mori K, Li JY et al (2007) Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18: 407-413
93. Mishra J, Ma Q, Prada A et al (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543
94. Supavekin S, Zhang W, Kucherlapati R et al (2003) Differential gene expression following early renal ischemia/reperfusion. Kidney Int 63: 1714-1724
95. Zappitelli M, Washburn KK, Arikan AA, et al (2007) Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 11: R84
96. Wheeler DS, Devarajan P, Ma Q et al (2008) Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med 36: 1297-1303
97. Wagener G, Jan M, Kim M et al (2006) Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105: 485-491
98. Bennett M, Dent CL, Ma Q et al (2008) Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 3: 665-673
99. Mishra J, Dent C, Tarabishi R et al (2005) Neutrophil gelatinase- associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365: 1231-1238
100. Ling W, Zhaohui N, Ben H et al (2008) Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 108: c176-c181
101. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S (2006) Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 26: 287-292
102. Nickolas TL, O'Rourke MJ, Yang J et al (2008) Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 148: 810-819
103. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N et al (2008) Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transpl 23: 414-416
104. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH (2010) Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 16: 49-54
105. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2008) Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 10: 997-1000
106. Damman K, van Veldhuisen DJ, Navis G et al (2010) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96: 1297-1302
107. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL et al (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 27: 4135-4142
108. Van Timmeren MM, Van den Heuvel MC, Bailly V, Bakker SJ, Van GH, Stegeman CA (2007) Tubular kidney injury molecule- 1 (KIM-1) in human renal disease. J Pathol 212: 209-217
109. Meyers JH, Chakravarti S, Schlesinger D, Illes Z, Waldner H, Umetsu SE et al (2005) TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol 6: 455-464
110. Kramer AB, van Timmeren MM, Schuurs TA, Vaidya VS, Bonventre JV, van Goor H et al (2009) Reduction of proteinuria in adriamycin-induced nephropathy is associated with reduction of renal kidney injury molecule-1 (Kim-1) over time. Am J Physiol Renal Physiol 276: 1136-1145
111. Van Timmeren MM, Bakker SJ, Vaidya VS, Bailly V, Schuurs TA, Damman J et al (2006) Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol 291: 456-464
112. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290: 517-529
113. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H et al (2007) Urinary N-acetyl-b-D-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 18: 904-912
114. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I et al (2009) Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 53: 16-25
115. Parikh CR, Lu JC, Coca SG, Devarajan P (2010) Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise. Ann Clin Biochem 47: 301-312
116. Nauta FL, Boertien WE, Bakker SJ et al (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34(4): 975-981
117. Hamada Y, Kanda T, Anzai T et al (1999) N-acetyl-beta- D-glucosaminidase is not a predictor, but an indicator of kidney injury in patients with cardiac surgery. J Med 30: 329-336